Next Article in Journal
Diverse Biological Activity of Benzofuroxan/Sterically Hindered Phenols Hybrids
Next Article in Special Issue
The Adapted POM Analysis of Avenanthramides In Silico
Previous Article in Journal
Clearing and Masking Agents in Pretargeting Strategies
Previous Article in Special Issue
The In Vitro Anti-Parasitic Activities of Emodin toward Toxoplasma gondii
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L.

by
Shaza M. Al-Massarani
1,
Latifah S. Aldurayhim
1,
Ibtisam A. Alotaibi
1,
Mostafa W. M. Abdelmageed
1,
Md Tabish Rehman
1,
Omer A. Basudan
1,
Maged S. Abdel-Kader
2,3,
Mohamed F. Alajmi
1,
Fatma M. Abdel Bar
2,4,
Perwez Alam
1,
Maram M. Al Tamimi
1 and
Ali A. El Gamal
1,4,*
1
Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2
Pharmacognosy Department, College of Pharmacy, Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
3
Department of Pharmacognosy, College of Pharmacy, Alexandria University, Alexandria 21215, Egypt
4
Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, El Mansoura 35516, Egypt
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(4), 498; https://doi.org/10.3390/ph16040498
Submission received: 23 January 2023 / Revised: 17 March 2023 / Accepted: 24 March 2023 / Published: 27 March 2023

Abstract

:
Phytochemical investigation of the ethanolic extract of the aerial parts of Sisymbrium irio L. led to the isolation of four unsaturated fatty acids (14), including a new one (4), and four indole alkaloids (58). The structures of the isolated compounds were characterized with the help of spectroscopic techniques such as 1D, 2D NMR, and mass spectroscopy, and by correlation with the known compounds. In terms of their notable structural diversity, a molecular docking approach with the AutoDock 4.2 program was used to analyze the interactions of the identified fatty acids with PPAR-γ and the indole alkaloids with 5-HT1A and 5-HT2A, subtypes of serotonin receptors, respectively. Compared to the antidiabetic drug rivoglitazone, compound 3 acted as a potential PPAR-γ agonist with a binding energy of −7.4 kcal mol−1. Moreover, compound 8 displayed the strongest affinity, with binding energies of −6.9 kcal/mol to 5HT1A and −8.1 kcal/mol to 5HT2A, using serotonin and the antipsychotic drug risperidone as positive controls, respectively. The results of docked conformations represent an interesting target for developing novel antidiabetic and antipsychotic drugs and warrant further evaluation of these ligands in vitro and in vivo. On the other hand, an HPTLC method was developed to quantify α-linolenic acid in the hexane fraction of the ethanol extract of S. irio. The regression equation/correlation coefficient (r2) for linolenic acid was Y = 6.49X + 2310.8/0.9971 in the linearity range of 100–1200 ng/band. The content of α-linolenic acid in S. irio aerial parts was found to be 28.67 μg/mg of dried extract.

1. Introduction

Plants of the mustard family (Brassicaceae), such as broccoli, mustard, cabbage, cauliflower, kale, and turnip, have dietary value, economic importance, and traditional medicinal uses [1]. Sisymbrium is a member of the family Brassicaceae with around 90 species endemic to temperate Asia, Europe, the Mediterranean, southern Africa, and Australia. Some of these species were used in folkloric medicine to treat bronchitis, stomach ailments, voice disorders, sore throats, and as poison antidotes [2,3]. Previous phytochemical studies on Sisymbrium have led to the isolation of glucosinolate glycosides, flavonoids, alkaloids, anthraquinones, and steroids [3,4,5].
Sisymbrium irio L. is an edible yellow-flowered plant, native to Asia, North Africa, and southern Europe, and has been transferred by migrants, either accidentally or intentionally, to profuse areas around the world. It is classified as an invasive and notorious weed in several countries [3]. Like most Brassicaceae plants, S. irio is well-known for its highly nutritional value and rich content of protein, minerals, fatty acids, and vitamins, both in the seeds and aerial parts [6]. Moreover, it is used in folkloric medicine to treat different ailments due to its antioxidant, antimicrobial, anti-inflammatory, and diuretic properties [7,8,9].
Rivoglitazone, together with rosiglitazone and pioglitazone are thiazolidinedione-derivatives. They act by binding to the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ). Rivoglitazone, reported as the most potent PPAR-γ agonist, decreases plasma glucose and triglyceride levels in a dose-dependent manner in animals. The efficacy and safety of rivoglitazone for the treatment of type 2 diabetes mellitus patients have been proven by stage II and stage III clinical studies [10].
Serotonin, 5-HT (5-hydroxytryptamine), is a well-known neurotransmitter due to its vital role in many physiological functions, such as sleep, appetite, and pain perception in several pathological disorders, including migraine, depression, and anxiety [11]. Thus, 5-HT receptors are important therapeutic targets for the treatment of several CNS conditions. On the other hand, risperidone is an atypical antipsychotic medication. It acts as an antagonist for the serotonin 5-HT2A receptor with high affinity, leading to serotonin and norepinephrine reuptake inhibition. It has also been used as an adjunct for severe depression and in the treatment of non-psychotic unipolar depression [12].
The long traditional history of ‘plant-based therapies’ has always been a motivation to investigate the potential pharmacological activities of the isolated secondary metabolites through molecular docking, a cost-effective and reliable computational methodology that has been a valuable tool to discover novel drug candidates [13,14].
In the current study, we describe the isolation and identification of eight compounds belonging to two classes (unsaturated fatty acids and indole alkaloids) and perform comparative molecular docking and binding free energy calculations to rank the identified compounds based on their binding affinities with the ligand-binding domains (LBD) of the therapeutic targets PPAR-γ and 5-HT1A and 5-HT2A, respectively. We also developed a sensitive HPTLC method for the quantification of the biomarker compound α-linolenic acid in the ethanol extract of S. irio.

2. Results

2.1. Identification of Isolated Compounds

The structures of the isolated compounds (Figure 1) were elucidated by 1D, 2D NMR analyses, MS, and by comparing with the literature data (Tables S1 and S2) [15,16,17,18,19,20,21].
Three known fatty acids (13) were identified as (7Z,10Z,13Z)-hexadecatrienoic acid (roughanic acid) (RA) (1) [15], (9Z,12Z,15Z)-octadecatrienoic acid (α-linolenic acid) (2) [16,17], and 8,11,12-trihydroxy-9Z-octadecanoic acid (3) [18], and the indole alkaloids (58) were identified as 1H-indole-3-acetonitrile (5) [19], 1-methoxyindole 3-acetonitrile (6) [19], 1-methoxy-1H-indole-3-carboxamide (7) [20], and α-amino-3-indole propanamide (L-tryptophanamide) (8) [21].
Compound 4 was isolated as a white amorphous solid. The HRESIMS showed quasi-molecular ion peaks at m/z 329.2325 [M+H]+ and 351.2140 [M+Na]+, consistent with a molecular weight of 328 amu, and a molecular formula of C18H32O5. IR absorption at 3315, 1697, and 1455 cm−1 indicated the presence of hydroxyl group, carboxylic group, and olefinic double bonds, respectively.
The 13C NMR spectrum and DEPT experiment in CD3OD revealed 4 to be C18-aliphatic acid, comprising one carboxylic group: C-1 (δC 177.9); four Sp2 methines forming two double bonds: C-9 (δC 136.5), C-10 (δC 131.0), C-15 (δC 126.3), and C-16 (δC 134.4); three oxygen-bearing Sp3 methines: C-8 (δC 73.0), C-11 (δC 75.8), and C-12 (δC 75.7); nine methylenes; and one methyl group: C-18 (δC 14.6) (Table 1). Furthermore, the 1H NMR spectrum showed a terminal methyl group: H3-18 (δH 0.85, t, J = 7.4 Hz); one methylene triplet: H2-2 (δH 2.16, t, J = 7.3 Hz); three oxygenated methines: H-8 (δH 3.98, m), H-11 (δH 3.85, t, J = 6.0 Hz), and H-12 (δH 3.38, m); and four olefinic protons of two cis-ene functions H-9/10 at (δH 5.60, m) and H-15/16 at (δH 5.34, m) (Table 1).
The combined analysis of the COSY and HSQC spectra of 4 allowed establishing a continuous chain of carbon atoms from C-2 to C-18, which was further corroborated by HMBC correlations as shown in Figure 2. Moreover, the locations of hydroxyl groups and double bonds were also identified using COSY and HMBC experiments and confirmed at C-8, C-11, and C-12 for the three hydroxyl groups; and at C-9/10 and C-15/16 for the two olefinic double bonds. The Z-configuration of the double bonds was judged from their small coupling constant (J < 10 Hz) compared with the reported E-configuration [22,23].
Furthermore, the HMBC spectrum revealed key correlations between H2-2 (δH 2.16) and C-1 (δC 177.9) and C-4 (δC 30.1); H-8 (δH 3.98) and C-10 (δC 131.0); H-9 (δH 5.60) and C-11 (δC 75.8); H-10 (δH 5.60) and C-12 (δC 75.7); H-15 (δH 5.34) and C-13 (δC 31.5); H-14 (δH 1.22) and C-16 (δC 134.4); H-17 (δH 1.95) and C-15 (δC 126.3); and H3-18 (δH 0.85) and C-16 (δC 134.4) and C-17 (δC 21.6) (Figure 2). Accordingly, the structure of 4 was identified as 8,11,12-trihydroxy-9Z,15Z-octadecadienoic acid.

2.2. Analysis of Molecular Docking

2.2.1. Molecular Docking of Fatty Acids (14) with PPAR-γ

The isolated fatty acids (14) from S. irio were subjected to molecular docking experiments with peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG), also known as the glitazone reverse insulin resistance receptor, based on the reported antidiabetic activity for similar compounds [24,25,26,27]. The relative binding of fatty acids to the PPAR-γ substrate-binding site is described in Table 2 and Figure 3 and Figure 4. The details of the protein–ligand interaction are presented in Supplementary Table S3.
It is obvious that all isolated fatty acids have a docking energy in the range of −6.0 to −7.4 kcal/mol (Table 2), and the lowest binding energy was revealed by compound 3. To strengthen our finding, the binding potentials of (14) were compared with rivoglitazone as a positive control. The details of interactions between PPAR-γ and fatty acids, along with rivoglitazone, are discussed in the subsequent sections.
The analysis revealed that the PPAR-γ–rivoglitazone complex was stabilized by hydrophobic bonding (Figure 3A,B), including two Pi-Sigma hydrophobic bonds with ILE341 and three amide-Pi-stacked interactions with GLY284 (two interactions) and CYS285 (one interaction). Further, there were five Pi–Alkyl hydrophobic interactions with CYS285 (two interactions), ARG288 (two interactions), and LEU330 (one interaction); and one Pi–Pi T-shaped hydrophobic interaction with HIS449 (Figure 3C). In addition, the protein–ligand complex was stabilized by three Pi–S bonds with MET348 (two interactions) and MET364 (one interaction); two Pi-donor hydrogen bonds with CYS285 and SER289; and one conventional hydrogen bond with TYR473. The van der Waals interactions were also present with amino acid residues like ARG280, ILE281, PHE282, GLN286, HIS323, ILE326, TYR327, VAL339, LEU353, LEU453, and LEU469. The PPAR-γ–rivoglitazone complex was stabilized by an estimated free energy of −8.2 kcal mol−1, which corresponds to a dissociation constant of 1.03 × 106 M−1 (Table 2).
Furthermore, compound 1 was found to bind at the central binding cavity of PPAR-γ and the compound 1–PPAR-γ complex was mainly stabilized by hydrophobic interactions (Figure 4A). Compound 1 formed one hydrogen bond with HIS449 and four hydrophobic (alkyl) interactions with PHE226, ALA292, ILE296, and MET329 (Figure 4A). In addition, compound 1 formed van der Waals interactions with CYS285, GLN286, ARG288, SER289, GLU295, HIS323, ILE325, ILE326, TYR327, LEU330, LEU333, LYS367, LEU453, LEU465, LEU469, and TYR473. The binding energy and dissociation constant for the compound 1–PPAR-γ interaction were −6.7 kcal mol−1 and 8.21 × 104 M−1, respectively (Table 2).
The analysis of molecular docking also suggests that compound 2 occupied the active site of PPAR-γ (Figure 4B). The compound 2–PPAR-γ complex was stabilized by one hydrogen bond with HIS449 and two hydrophobic (alkyl) interactions with MET329 and LEU333 (Figure 4B). In addition, compound 2 formed van der Waals interactions with LEU228, PHE282, CYS285, ALA292, GLN286, ARG288, SER289, HIS323, TYR327, LEU330, SER332, ILE326, PHE363, MET364, LEU453, LEU465, LEU469, and TYR473. Gibb’s free energy of the complex formation was −6.0 kcal mol−1, which corresponds to a dissociation constant of 2.52 × 104 M−1 (Table 2).
The compound 3–PPAR-γ complex was mainly stabilized by hydrogen bonds and hydrophobic interactions. Compound 3 formed five hydrogen bonds with CYS285 (two bonds), ARG288, SER289, and MET329. It also interacted with PPAR-γ through three hydrophobic (alkyl) interactions with ILE281, PHE282, and CYS285 (Figure 4C). In addition, compound 3 formed van der Waals interactions with LEU228, GLN286, ALA292, ILE326, TYR327, LEU330, SER332, LEU333, LEU356, PHE360, PHE363, MET364, LYS367, and HIS449. The binding energy and dissociation constant for the compound 3–PPAR-γ interaction were −7.4 kcal mol−1 and 2.68 × 105 M−1, respectively (Table 2).
Finally, the analysis of the compound 4–PPAR-γ interaction revealed that the complex was stabilized by hydrogen bonds as well as hydrophobic (alkyl) interactions. Compound 4 formed two hydrogen bonds with CYS285 and SER289 and one Pi–Sigma bond with PHE282. Moreover, compound 4 interacted hydrophobically (alkyl) with ALA292, ILE326, and MET329 (Figure 4D). In addition, compound 4 formed van der Waals interactions with GLN286, ARG288, HIS323, TYR327, LEU330, LEU333, PHE363, MET364, LYS367, HIS449, LEU453, LEU465, LEU469, and TYR473. Gibb’s free energy of the complex formation was −6.1 kcal mol−1, which corresponds to a dissociation constant of 2.98 × 104 M−1 (Table 2).

2.2.2. Molecular Docking of Compounds 58 with 5-HT1A and 5-HT2A Serotonin Receptors

Indole compounds (58) were screened for antidepressant activity using 5-HT1A and 5-HT2A serotonin receptors as potential targets. The relative binding of indole compounds is described in Table 3 and Table 4 and Figure 5, Figure 6, Figure 7 and Figure 8, and the detailed protein–ligand interaction is presented in Supplementary Tables S4 and S5.
The results exhibited that all indole compounds (58) were able to bind to the substrate binding site of 5-HT1A (Figure 5A,B) and 5-HT2A (Figure 7A,B) receptors, with more affinity towards the 5-HT2A receptor, and their binding energies varied in the range between −6.4 and −6.9 kcal mol−1 and between −7.3 and −8.1 kcal mol−1, respectively. The binding potentials of indole compounds towards 5-HT1A and 5-HT2A receptors were compared with serotonin and risperidone, respectively, as positive controls (Table 3 and Table 4). The details of interactions between indole compounds and 5-HT1A and 5-HT2A, along with positive controls, are discussed in the subsequent sections.

5-HT1A Binding Interaction

The molecular docking of serotonin (positive control) showed that it occupied the active site of 5-HT1A and interacted primarily through hydrogen bonds and hydrophobic interactions (Figure 5A,B). It formed four hydrogen bonds with ASP116, VAL117, THR121, and TYR390; one Pi–Pi T-shaped hydrophobic interaction with PHE361; and four Pi–Alkyl hydrophobic interactions with VAL117 (two interactions), ILE189, and ALN203 (Figure 5C). In addition, the protein–ligand complex was stabilized by van der Waals interactions with CYS120, ILE124, ILE167, SER199, PHE362, ALA365, and ASN386. The 5-HT1A–serotonin complex was stabilized by −6.1 kcal mol−1 free energy, which corresponds to a dissociation constant of 6.1 × 104 M−1 (Table 3).
The analysis of the 5-HT1A5 interaction revealed that the complex was stabilized by an electrostatic (Pi–Anion) interaction with ASP116, two hydrogen bonds with CYS120, and two Pi–Pi T-shaped hydrophobic interactions with PHE361 (Figure 6A). In addition, it formed van der Waals interactions with VAL117, THR121, ILE124, ALA203, TRP358, PHE362, ASN386, GLY389, and TYR390. Gibb’s free energy of the complex formation was −6.4 kcal mol−1, which corresponds to a dissociation constant of 4.94 × 104 M−1 (Table 3).
Further, the analysis revealed that the 5-HT1A6 complex was stabilized mainly by many hydrogen bonds and hydrophobic interactions, including one hydrogen bond with SER199 and five hydrophobic interactions with VAL117 (Pi–Sigma and Pi–Alkyl), CYS120 (Pi–Alkyl), ILE189 (Pi–Alkyl), and PHE361 (Pi–Pi T-shaped) (Figure 6B). In addition, compound 6 formed van der Waals interactions with ASP116, THR121, ILE124, THR196, THR200, ALA203, PHE362, and ALA365. The binding energy and dissociation constant for the compound 6–5-HT1A interaction were −6.4 kcal mol−1 and 4.94 × 104 M−1, respectively (Table 3).
The analysis of molecular docking also suggests that the 5HT1A7 complex was stabilized by hydrophobic interactions, including two Pi–Sigma hydrophobic interactions with VAL117, one Pi–Alkyl interaction with ILE189, one Pi–Sulfur bond with CYS120, and one Pi–Pi T-shaped bond with PHE361 (Figure 6C). In addition, it formed van der Waals interactions with ASP116, THR121, ILE124, TRY195, SER199, ALA203, and PHE362. Gibb’s free energy of the complex formation was −6.5 kcal mol−1, which corresponds to a dissociation constant of 5.85 × 104 M−1 (Table 3).
Finally, Compound 8 was able to bind at the central binding cavity of 5-HT1A, and the resulting complex was mainly stabilized by hydrophobic interactions (Figure 6D). Compound 8 formed one hydrogen bond with THR196 and six hydrophobic (Pi–Alkyl) interactions with ILE189, LYS191, ALA365, and PRO369 (Figure 6D). In addition, it formed van der Waals interactions with VAL117, SER190, TYR195, SER199, THR200, PHE361, and PHE362. The binding energy and dissociation constant for compound 8 and 5-HT1A interactions were −6.9 kcal mol−1 and 1.15 × 105 M−1, respectively (Table 3).

5-HT2A Binding Interaction

The molecular docking of risperidone showed that it occupied the active site of 5-HT2A and interacted primarily through hydrophobic interactions (Figure 7A,B). It formed two hydrogen bonds with SER131 and SER159 and a halogen bond with ASN363. Also, it formed two Pi–Sigma hydrophobic interactions with TRP336 and VAL366, one Pi–Pi T-shaped hydrophobic interaction with PHE340, two Alkyl hydrophobic interactions with ILE163 and VAL366, and seven Pi–Alkyl hydrophobic interactions with VAL156, PHE243, PHE332, TRP336, PHE339, PHE340, and VAL366 (Figure 7C). In addition, the protein–ligand complex was stabilized by van der Waals interactions with TYR139, TRP151, ASP155, THR160, LEU228, GLY238, SER242, and TYR370. The 5-HT2A–risperidone complex was stabilized by −11.8 kcal mol−1 free energy, which corresponds to a dissociation constant of 4.52 × 108 M−1 (Table 4).
The analysis of molecular docking suggests that compound 5 occupied the active site of 5-HT2A and the formed complex was stabilized by two hydrogen bonds with SER159 and THR160, and six hydrophobic interactions with TRP336, PHE340, VAL156, and ILE163 (Figure 8A). In addition, compound 5 formed van der Waals interactions with ASP155, SER242, PHE243, PHE332, PHE339, and TYR370. Gibb’s free energy of the complex formation was −7.3 kcal mol−1, which corresponds to a dissociation constant of 2.60 × 105 M−1 (Table 4).
Moreover, the analysis revealed that the 5-HT2A6 complex was stabilized mainly by hydrogen bonds and hydrophobic interactions. Compound 6 formed one hydrogen bond with SER242 and eight hydrophobic interactions with TRP336, PHE340, SER159, THR160, VAL156, and ILE163 (Figure 8B). In addition, compound 6 formed van der Waals interactions with ASP155, THR160, GLY238, PHE243, PHE332, and PHE339. The binding energy and dissociation constant for compound 5-HT2A6 interactions were −7.5 kcal mol−1 and 3.17 × 105 M−1, respectively (Table 4).
The analysis of molecular docking suggests that compound 7 occupied the active site of 5-HT2A, and the complex was stabilized via hydrogen bond formation and hydrophobic interactions. Compound 7 formed two hydrogen bonds with ASP155, four Pi–Pi T-shaped hydrophobic interactions with TRP336 and PHE340, one Pi–Alkyl interaction with VAL156, and two Amide–Pi stacked interactions with SER159 and THR160 (Figure 8C). In addition, compound 7 formed van der Waals interactions with LEU123, THR160, ILE163, GLY238, SER242, PHE243, PHE332, PHE339, and TYR370. Gibb’s free energy of the complex formation was −7.4 kcal mol−1, which corresponds to a dissociation constant of 2.68 × 105 M−1 (Table 4).
Finally, the analysis of the 5-HT2A8 complex revealed that it was mainly stabilized by the formation of three hydrogen bonds with ASP155, THR160, and TYR370; three Pi–Pi T-shaped hydrophobic interactions with TRP336 and PHE340; and two Pi–Alkyl hydrophobic interactions with ILE163 and VAL156 (Figure 8D). A salt bridge was also formed between ASP155 and compound 8. In addition, it formed van der Waals interactions with LEU123, SER159, SER242, PHE243, PHE332, PHE339, and VAL366. The binding energy and dissociation constant for 5-HT2A8 interactions were −8.1 kcal mol−1 and 2.68 × 105 M−1, respectively (Table 4).

2.3. Prediction of Physicochemical, Pharmacokinetic, Drug-Likeness, and Toxicity

The physicochemical, pharmacokinetic (ADME parameters), drug-likeness, and toxicity properties of the investigated compounds were predicted using the SwissADME online tool [28]. These properties include lipophilicity, water-solubility, topological polar surface area (TPSA), GI absorption, blood–brain barrier (BBB) permeability, P-glycoprotein pump (P-gp) efflux, Lipinski’s rules, bioavailability, PAINS, and CYP450 inhibition. In general, the results showed compliance with Lipinski’s rules (Table 5).
The radar plot (Figure S9) is a representation of the mean values of six descriptors that are significant for oral bioavailability and used for a rapid appraisal of drug-likeness, including molecular size (SIZE), polarity (POLAR), lipophilicity (LIPO), flexibility (FLEX), saturation (SATU), and solubility (INSOLU). The red lines of the investigated molecules have to fall entirely in the pink area of the radar plot to be considered drug-like [28]. Most of the investigated compounds fall inside the pink area of their radar representations, indicating potential drug-like properties.
Lipophilicity is a crucial property for BBB permeability, a major obstacle in the delivery of antidepressant drugs to the brain [29]. Compounds 5, 6, and 7 showed potential BBB permeability; however, the permeability of the polar indole derivative (8) and the polyhydroxylated fatty acids (3 and 4) was not probable. The P-gp reduces the drug permeability through the BBB by allowing the efflux of many drugs back into the blood (multidrug resistance). No active efflux was observed by the P-gp for all investigated indole derivatives (Figure S10).

2.4. Analysis of Free Energy Calculations

The free energy (MM-GBSA) of the interaction between a protein and a ligand sheds light on the effect of solvent on the formation of a protein–ligand complex. Here, we calculated the free energy of the interaction of PPAR-γ with compounds 14, and serotonin receptors (5-HT1A and 5-HT2A) with compounds 58 (Table 6). It is clear that the free energies of compounds 1 (−54.55 kcal/mol) and 3 (−57.23 kcal/mol) were the lowest, suggesting that they formed a stable complex with PPAR-γ. Likewise, the free energies of compound 8 (−57.98 kcal/mol) for 5-HT1A and compound 8 (−57.90 kcal/mol) for 5-HT2A were the lowest, indicating that these compounds interacted favorably with 5-HT1A and 5-HT2A, respectively. It is also imperative to note that van der Waals interactions (ΔGvdW), Coulombic interactions (ΔGCoulomb), and non-polar solvation energy (ΔGSA) or lipophilic interactions (ΔGSol_Lipo) were the primary driving forces for the formation of a stable protein–ligand complex. On the other hand, polar solvation energy (ΔGSolv or ΔGSolGB) and covalent (ΔGCovalent) interactions were the main forces to destabilize a protein–ligand complex. It is worth noting that we selected only compounds 1 and 3 for PPAR-γ, and compound 8 for 5-HT1A as well as 5-HT2A to gain an in-depth analysis of interaction by molecular dynamics (MD) simulation.

2.5. Analysis of Moelcular Dynamics Simulation (MDS)

2.5.1. Root Mean Square Deviation (RMSD)

RSMD is a measure of deviation in the structure of a protein in the presence or absence of a ligand from its initial structure during the course of simulation, which in turn reflects on the system’s stability [30]. In this study, RMSDs in Cα-atoms of PPAR-γ, 5-HT1A, and 5-HT2A and their complexes, namely PPAR-γ-1, PPAR-γ-3, 5-HT1A-8, and 5-HT2A-8 were determined (Figure 9). The RMSDs (between 20 and 100 ns) of PPAR-γ, 5-HT1A, and 5-HT2A in the absence of any ligand fluctuated within 1.23–1.91 Å, 2.25–3.03 Å, and 1.39–2.57 Å, respectively, with average RMSDs of 1.79 ± 0.07 Å, 2.83 ± 0.10 Å, and 1.89 ± 0.06 Å, respectively. Further, the RMSDs in Cα-atoms of PPAR-γ (during 20–100 ns) in the presence of compounds 1 and 3 were within the range of 1.52–1.98 Å and 1.25–1.64 Å, respectively. The average RMSDs of PPAR-γ–1 and PPAR-γ–3 complexes were 1.82 ± 0.07 Å and 1.41 ± 0.04 Å, respectively (Figure 9A). Similarly, the RMSDs in Cα-atoms of 5-HT1A and 5-HT2A (during 20–100 ns) in the presence of compound 8 were within the range of 2.16–2.81 Å and 1.44–2.45 Å, respectively. The average RMSDs of 5-HT1A8 and 5-HT2A8 complexes were 2.44 ± 0.06 Å and 1.99 ± 0.05 Å, respectively (Figure 9B,C).

2.5.2. Root Mean Square Fluctuation (RMSF)

During MD simulation, any fluctuations in the side chain of a protein due to the binding of a ligand are measured by monitoring the RMSF. Here, the RMSF values of PPAR-γ 5-HT1A and 5-HT2A alone or in the presence of their respective ligands were determined as a function of simulation time (Figure 10). The RMSF plot of PPAR-γ–1 and PPAR-γ–3 complexes overlapped with the RMSF plot of PPAR-γ alone, suggesting the absence of any significant changes in PPAR-γ conformation due to its interaction with compounds 1 and 3 (Figure 10A). Similarly, the RMSF plots of 5-HT1A8 and 5-HT2A8 complexes overlapped with the RMSF plots of 5-HT1A and 5-HT2A alone, respectively, showing that there were no significant changes in 5-HT1A and 5-HT2A due to the binding of ligands and hence the formation of stable protein–ligand complexes (Figure 10B,C). Any minor fluctuations in RMSF plots were due to the binding of ligands to proteins.

2.5.3. Radius of Gyration (Rg)

The compactness of a protein–ligand complex, and hence its stability, are often measured by observing variation in Rg as a function of simulation time. We determined the Rg of PPAR-γ, 5-HT1A, and 5-HT2A alone and their complexes, namely PPAR-γ–1, PPAR-γ–3, 5-HT1A8, and 5-HT2A8, during 100 ns of simulation (Figure 11). During 20–100 ns, the Rg values of PPAR-γ, 5-HT1A, and 5-HT2A alone varied within 1.90–1.94 Å, 1.91–1.94 Å, and 1.92–1.95 Å, with average values of 1.93 ± 0.03 Å, 1.94 ± 0.05 Å, and 1.94 ± 0.06 Å, respectively. The Rg values of PPAR-γ–1 and PPAR-γ–3 complexes during 20–100 ns fluctuated within 1.88–1.93 Å and 1.89–1.94 Å, with an average value of 1.92 ± 0.07 Å and 1.93 ± 0.07 Å, respectively (Figure 11A). Similarly, the Rg values of 5-HT1A8 and 5-HT2A8 complexes during 20–100 ns fluctuated within 1.90–1.94 Å and 1.92–1.96 Å, with average values of 1.94 ± 0.06 Å and 1.94 ± 0.07 Å, respectively (Figure 11B,C). These results clearly signify that the compounds remain settled within the binding pocket of their respective proteins and form a stable protein–ligand complex.

2.5.4. Solvent-Accessible Surface Area (SASA)

SASA is a measure of the exposure of protein–ligand complexes to their surrounding solvent molecules, which in turn indicates the stability of a protein–ligand complex. Here, we determined the SASA of PPAR-γ, 5-HT1A, and 5-HT2A alone and their complexes, namely PPAR-γ–1, PPAR-γ–3, 5-HT1A8, and 5-HT2A8 (Figure 12). During 20–100 ns, the SASA values of PPAR-γ, 5-HT1A, and 5-HT2A alone varied within 132–141 Å2, 159–165 Å2, and 157–172 Å2, with average values of 138 ± 4.3 Å2, 162 ± 5.1 Å2, and 165 ± 4.8 Å2, respectively (Figure 12). The SASA values of PPAR-γ–1 and PPAR-γ–3 complexes during 20–100 ns fluctuated within 138–152 Å2 and 139–149 Å2, with an average value of 143 ± 5.2 Å2 and 144 ± 7.1 Å2, respectively (Figure 12A). Similarly, the SASA values of 5-HT1A8 and 5-HT2A8 complexes during 20–100 ns fluctuated within 161–170 Å2 and 160–171 Å2, with an average value of 166 ± 6.3 Å2 and 167 ± 5.7 Å2, respectively (Figure 12B,C). These results clearly signify that the compounds remain seated within the binding pocket of their respective proteins and form a stable protein–ligand complex.

2.6. Principal Component Analysis (PCA) or Essential Dynamics (ED) Analysis

The global motion of a protein in the presence or absence of a ligand is generally monitored by PCA or ED [31]. In this study, the conformational sampling of Cα-atoms along PC1 and PC2 of PPAR-γ, 5-HT1A, and 5-HT2A was performed in the absence or presence of their respective compounds (Figure 13). A conformational state of a protein is represented by the red and black dots. On the other hand, each red and black cluster shows the presence of distinct energetically favorable conformational spaces.
The conformational subspace occupied by PPAR-γ alone spans −15 to +20 along PC1 (33.64%), and −15 to +15 along PC2 (14.06%). Further, the conformational spaces occupied by PPAR-γ in the presence of compounds 1 and 3 were in the range of −18 to +15 along PC1 (27.77%)/−12 to +15 along PC2 (9.41%), and −15 to +15 along PC1 (25.35%)/−12 to +12 along PC2 (13.82%) respectively (Figure 13A–C). It is noticeable that the first three eigenvalues of PPAR-γ alone or in the presence of compounds 1 and 3 occupied 55.0%, 45.5%, and 48.2% conformational variances, respectively. Similarly, the conformational subspace occupied by 5-HT1A alone spans −25 to +25 along PC1 (35.14%) and −15 to +22 along PC2 (15.95%). Further, the conformational space occupied by 5-HT1A in the presence of compound 8 was in the range of −20 to +20 along PC1 (22.19%)/−30 to +20 along PC2 (18.51%) (Figure 13D,E). Similarly, the conformational space occupied by 5-HT2A in the presence of compound 8 was in the range of −22 to +20 along PC1 (22.96%)/−20 to +30 along PC2 (17.06%) (Figure 13F,G).
Furthermore, the first three eigenvalues of 5-HT1A alone, 5-HT2A alone, 5-HT1A8 complex, and 5-HT2A8 complex occupied 58.1%, 49.4%, 56.4%, and 46.1% conformational variances, respectively. These results indicate that there was a marginal increase in the flexibility of 5-HT1A in the presence of compound 8, while the flexibility of PPAR-γ in the presence of compounds 1 and 3, and flexibility of 5-HT2A in the presence of compound 8 were similar to those of PPARγ alone and 5-HT2A alone, respectively.

2.7. HPTLC Analysis of α-Linolenic in the Aerial Parts of S. irio

The developed HPTLC method was found to furnish a compact spot for α-linolenic acid at Rf = 0.57 ± 0.004 (Figure S11A). The regression equation/correlation coefficient (r2) for α-linolenic acid was Y = 6.49X + 2310.8/0.9971 in the linearity range of 100–1200 ng/band. The limits of detection (28.89 ng/band), quantification (87.57 ng/band), and recovery (98.16–99.26%) were found satisfactory for α-linolenic acid. The intra-/inter-day precisions (% RSD) for the proposed method were 1.24–1.48/1.14–1.43, which indicated a good precision for the proposed method. The amount of α-linolenic acid was estimated by comparing the peak area of the standard with that of crude extract (Figure S11B,C). Figure S11D clearly reveals that all peaks of α-linolenic acid in the extract coincided with each other at the observed UV absorption maxima (λmax = 540). The estimated α-linolenic acid content in the hexane extract of aerial parts of S. irio was 28.67 μg/mg of dried extract.

3. Discussion

The chosen target for molecular docking analysis of the identified fatty acids was inspired by the activities reported in the literature for polyunsaturated fatty acids (PUFAs). PUFAs are known to reduce the risk of heart disease and heart attacks by refining blood lipids and endothelial function and by employing notable anti-inflammatory and anti-thrombotic effects [32]. They have a significant role in the treatment of type 2 diabetes through modulation of lipid and glucose homeostasis. They also play a vital role in Alzheimer’s disease and in some cancers [33].
PPAR-γ or PPARG is the peroxisome proliferator-activated receptor gamma, also known as the glitazone reverse insulin resistance receptor. It is a type II protein-regulating gene encoded by the PPAR-γ gene [34]. Polyunsaturated fatty acids (PUFAs) are known to function as agonists of PPAR-γ, a nuclear receptor that has been getting increasing interest as a novel therapeutic target for the treatment of diabetes and related metabolic disorders [35]. Studies demonstrated that activation of PPAR-γ by PUFA ligands results in a number of biologically beneficial effects, including stimulation of lipid and glucose metabolisms, anti-inflammatory effects, and favorable cardiovascular effects [36].
The results of docking of the fatty acids (14) revealed moderate interaction with PPAR-γ active residues that formed stable complexes with relatively high free energy, compared to the standard drug rivoglitazone. Compound 3 formed the most stable complex with the highest binding affinity (−7.4 kcal mol−1). On the other hand, the close structural similarity of indole alkaloids, some of which are of plant origin (exogenous agonists), to the endogenous neurotransmitter serotonin might explain the potential neurological activity of these compounds, as depression is mostly triggered by an imbalance in serotonin levels [37].
Assessment of the ADME properties of the isolated compounds revealed that all investigated compounds, except the polyunsaturated fatty acids 1 and 2, showed high predicted GIT absorption and oral bioavailability. Regarding metabolism, CYP450–1A2 showed possible inhibition by compounds 5, 6, and 7, whereas CYP2D6 showed potential inhibition by compounds 3 and 4, in contrast to 8, which showed no inhibition to all CYP450 subtypes. P-gp is extensively distributed in the capillary endothelial cells of the BBB and contributes to pumping xenobiotics back into the blood [38]. Bypassing the P-gp drug-efflux mechanism is a crucial property for drugs used in neurodegenerative diseases [38,39]. In other words, compounds that are not P-gp substrates are predictably more bioavailable in the brain [28]. Since no predictable active efflux was observed by the P-gp for the investigated indole derivatives (58), they can be delivered in appropriate concentrations to the brain and used in the treatment of neurological disorders, including depression [29], whereas 3 and 4 are probable P-gp substrates due to the presence of more rotatable bonds compared to indole derivatives (58) [40]. Also, no PAINS (Pan-assay interference compounds) alerts were detected for any of the tested compounds (18).
A study conducted on the extract of Mitragyna speciosa, which contains the indole alkaloids mitragynine, paynantheine, and speciociliatine as major constituents, induced an antidepressant-like effect in mouse models; the effect was speculated to be through the interaction with the hypothalamic–pituitary–adrenal (HPA) axis in the neuroendocrine system [41].
Another plant, Passiflora incarnata L. (passion flower), containing the indole alkaloids harman, harmol, and harmine, reduced anxiety and improved memory in rats in a dose-dependent manner. Cortical serotonin content was depleted, with increased levels of metabolites and increased turnover. It was found that the proposed mechanism of action of passion flower involved GABAA-receptors [42]. These facts motivated us to investigate the potential neurological activity of currently isolated indole alkaloids through docking into the 5-HT1A and 5-HT2A receptors. The serotonin receptor subtype 5-HT1A has been implicated in several neurological conditions, and 5-HT1A receptor agonism represents efficacious therapeutic potential for the treatment of major depression, anxiety, schizophrenia, and Parkinson’s disease.

4. Materials and Methods

4.1. Apparatus and Chemicals

IR spectrum was acquired using a JASCO 320-A spectrometer (JASCO International Co., Ltd., Easton, MD, USA). Normal and reversed-phase silica gels (Merck, Darmstadt, Germany) were used for column chromatography (CC) and thin-layer chromatography (TLC). The compounds were visualized on TLC by spraying with 15% H2SO4/ethanol, followed by heating.
NMR spectroscopy was performed using deuterated solvents in an UltraShield Plus 500 (Bruker, Billerica, MA, USA) spectrometer operating at 500 MHz for 1H and 125 MHz for 13C at the College of Pharmacy, Prince Sattam Bin Abdulaziz University. The two-dimensional NMR analyses (COSY, HSQC, and HMBC) were conducted using the standard Bruker pulse program. Chemical shift values are reported in δ (ppm) relative to an internal standard (TMS), and coupling constants (J) are reported in Hertz (Hz).
HRMS was performed using a Thermo Scientific UPLC RS Ultimate 3000 Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (Mundelein, IL, USA) combined with high-performance quadrupole precursor selection with high resolution, accurate-mass (HR/AM) Orbitrap™ detection. The instrument was located at Prince Sattam Bin Abdulaziz University, College of Pharmacy. The detection was performed in negative and positive modes, and the experiment run time was 1 min using nitrogen as the supplementary gas with a scan range from 160–1500 m/z.

4.2. Plant Material

The aerial parts of S. irio L. were collected from a farm near Riyadh city in the Najd region of Saudi Arabia in March 2019 and kindly identified by a taxonomist at the Pharmacognosy Department, College of Pharmacy, King Saud University. A voucher specimen (no. 14380) has been deposited in the herbarium of the Pharmacognosy Department, College of Pharmacy.

4.3. Extraction and Isolation of Compounds

The shade-dried aerial parts of the plant (1 kg) were coarsely powdered and extracted with 80% ethanol. The ethanolic extract was concentrated under reduced pressure using a rotary evaporator (R-210, BUCHI) to give 28 g of brownish-black mass. The obtained extract was fractionated using different polarity solvents, starting with n-hexane (n-Hex.), followed by dichloromethane (CH2Cl2), and finally n-butanol (n-BuOH) to obtain the corresponding fractions.
The n-Hex. fraction (8 g) was chromatographed over a silica gel column, starting with CHCl3 as a mobile system, and gradually increasing polarity with MeOH. The eluted fractions were monitored with TLC, and similar fractions were combined to end up with 16 main fractions (n-Hex.1–16). Fraction n-Hex.2, eluted with 2% MeOH/CHCl3, was purified using chromatotron (CPTL, silica gel 60 GF254, 1 mm), 5% EtOAc/n-Hex. as mobile phase, to obtain compound 1 in pure form. Another part of the n-Hex.2 fraction was subjected to RP-18 column chromatography (CC) using 5% H2O/CH3CN as a solvent system to provide compounds 2 and 3 in pure forms.
Fraction n-Hex.7, eluted with 5% MeOH/CHCl3, was subjected to Rp-18 CC using 5% H2O/MeOH as a solvent system to give compound 4. Fraction n-Hex.16, eluted with 20% MeOH/CHCl3, was purified by using centrifugal thin-layer chromatography (mobile phase: 0.5% MeOH/EtOAc) to provide compound 5.
Part of the CH2Cl2 fraction (6 g) was purified using a chromatotron (1 mm, mobile phase, 4% MeOH/CHCl3) to obtain several subfractions (1–28); further purification of sub-fraction 17 resulted in compound 6 in pure form.
Part of the n-BuOH fraction (5 g) was loaded on top of a silica gel column and eluted with a gradient solvent system of n-BuOH–water–acetic acid 13:2:1 v/v/v to produce five subfractions (n-BuOH.1–5). Sub-fractions n-BuOH.1 and n-BuOH.2, were purified by Rp-18 CC using 10% CH3CN/H2O to yield compounds 7 and 8, respectively.

4.4. Molecular Docking

Interaction of the active constituents of S. irio with serotonin receptors (5-HT1A and 5-HT2A) and PPAR-γ was studied by performing molecular docking using AutoDock 4.2 [43,44]. The two-dimensional structures of ligands (active constituents) were drawn in ChemDraw Ultra 7.0 and converted to three-dimensional structures using OpenBabel. In ligands, Gasteiger partial charges were added, non-hydrogen atoms were merged, and rotatable bonds were defined using AutoDock Tools (ADT). The energies of all the ligands were minimized using the Universal Forcefield (UFF). The three-dimensional coordinates of different drug targets were obtained from the Protein Data Bank (www.rcsb.org, accessed on 21 August 2022). The X-ray crystal structure (PDB ID: 5U5L) of PPAR-γ in complex with rivoglitazone was resolved to 2.55 Å [10]. Similarly, the X-ray crystal structures of both serotonin receptors, namely 5-HT1A (PDB ID: 7E2Y) and 5-HT2A (PDB ID: 6A93), bound with serotonin and risperidone, respectively, were resolved to 3.00 Å [45,46].
Prior to molecular docking, the target proteins were cleaned by removing any heteroatoms, including non-essential water molecules, and adding hydrogen atoms. Also, Kollman-united atom type charges and solvation parameters were added with the help of ADT. For PPAR-γ, grid boxes were defined as 35Å × 35Å × 35Å centered at −5 Å, 33 Å, and 131 Å coordinates. Similarly, the dimensions of grid boxes of 5-HT1A and 5-HT2A were set at 28Å × 28Å × 28Å placed at 101 Å, 115 Å, and 108 Å; and 35Å × 28Å × 29Å centered at 16 Å, −0.2Å, and 60Å, respectively. Molecular docking was performed using the Lamarck Genetic Algorithm (LGA) along with the Solis and Wets search methods. The position, torsion, and orientation of ligands were set randomly, and all rotatable torsions were released. For each docking run, a maximum of 2.5 × 106 energy calculations were computed. The population size, translational step, quaternions, and torsion steps were set at 150, 0.2, 5, and 5, respectively. For each docking experiment, the lowest-energy docked structure was selected from 10 runs. Discovery Studio Visualizer was used to prepare and analyze the results and prepare figures. The dissociation constant (Kd) was evaluated from binding free energies (ΔG) using the following equation.
Δ G = R T l n K d
where R and T were the universal gas constant (=1.987 cal/mol/K) and temperature (=298K), respectively.

4.5. Prediction of Physicochemical, Pharmacokinetic, Drug-Likeness, and Toxicity

The physicochemical, pharmacokinetic, drug-likeness, and toxicity properties of the investigated compounds were predicted using the SwissADME web tool hosted by the Swiss Institute of Bioinformatics (http://www.sib.swiss, accessed on 24 August 2022) [28].

4.6. Molecular Dynamics Simulation (MDS)

The MDS of PPARγ, 5-HT1A, and 5-HT2A along with their respective ligands (compounds 1, 3, 7, and 8) was performed using Desmond-2018 (Schrodinger, LLC, NY, USA), as described earlier [47,48]. The MDS was performed in an orthorhombic box by placing the initial protein–ligand docked pose at the center of the box, keeping a distance of at least 10 Å from the box boundaries. The simulation box was solvated with TIP3P water molecules, and Na+ or Cl ions were added to neutralize the system. Salt (150 mM NaCl) was added to the system to mimic the physiological condition. The system was iterated with 1000 steps with a convergence criterion of 1 kcal/mol/Å using an OPLS3e force field in order to minimize its energy. A 100 ns production run was initiated using the OPLS3e force field under NPT conditions of 298 K temperature and 1 bar pressure. A Nose–Hoover chain thermostat and Martyna–Tobias–Klein barostat were employed to maintain the NPT conditions of the system, respectively [49,50]. A time step of 2 fs was kept in all MDS, and at every 10 ps, energies and structures were saved in the trajectory. The trajectories were analyzed for root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), and solvent-accessible surface area (SASA).

4.7. Free Energy Calculations

The free energy of protein–ligand complex formation was computed by the MM–GBSA (Molecular Mechanics–Generalized Born Surface Area) approach using the Prime-2018 module (Schrodinger, LLC, New York, NY, USA), as described previously [51]. Briefly, the Molecular Mechanics (MM) approach was first used to locally optimize the docked complexes, and then their energies were minimized employing an OPLS3e force field along with a generalized Born surface area (GBSA) continuum solvent. The following relations were utilized to calculate the binding free energies of protein–ligand complexes:
Δ G B i n d = Δ E M M + Δ G S o l v _ G B + Δ G S A
Δ E M M = E c o m p l e x E p r o t e i n + E l i g a n d
where Ecomplex, Eprotein, and Eligand are the minimized energies of the protein–ligand complex, the protein alone, and the ligand alone, respectively;
Δ G s o l v _ G B = G s o l v G B ( c o m p l e x ) G s o l v G B p r o t e i n + G s o l v _ G B ( l i g a n d )
where Gsolv_GB(complex), Gsolv_GB(protein), and Gsolv_GB(ligand) are the free energies of solvation of the protein–ligand complex, the protein alone, and the ligand alone, respectively; and
Δ G S A = G S A ( c o m p e l x ) G S A p r o t e i n + G S A ( l i g a n d )
where GSA(complex), GSA(protein), and GSA(ligand) are the surface area energies of the protein–ligand complex, the protein alone, and the ligand alone, respectively.
In the Prime-MM/GBSA method, the free energy is calculated as follows:
Δ G B i n d = Δ G C o u l o m b + Δ G v d W + Δ G C o v a l e n t + Δ G H - b o n d + Δ G S o l _ L i p o + Δ G S o l v _ G B + Δ G P a c k i n g + Δ G S e l f - c o n t a c t

4.8. Principal Component Analysis (PCA) or Essential Dynamics (ED)

The collective motions of proteins along with their respective ligands were measured by employing a PCA or essential dynamics (ED) approach using the Bio3D package [52,53]. In this approach, first the protein’s translational and rotational motions are disregarded, followed by the calculation covariance matrix and its eigenvectors by superimposing the protein’s atomic coordinates onto a reference structure. Secondly, the symmetric matrix is diagonalized by an orthogonal transformation matrix, giving a diagonalized matrix of eigenvalues. The covariance matrix (C) is calculated using the following relation:
C i j = x i x i x j x j             i , j = 1,2 , 3 , , 3 N
where, N, xi/j, and <xi/j> represent the number of Cα-atoms, the Cartesian coordinates of the ith/jth Cα-atom, and time average of all the conformations, respectively.

4.9. Standardization of S. irio Extract by a Validated HPTLC Method

The standardization of S. irio extract was carried out by a validated high performance thin layer chromatography (HPTLC) method using α-linolenic acid as the marker compound. Chromatography was performed on a glass-backed silica gel 60 F254 HPTLC plate (20 × 10 cm). Different combinations of solvents were tested to develop the HPTLC method, and a mixture of acetone, n-hexane, and acetic acid in the proportion of 25:75:0.1 v/v/v was selected as the most suitable mobile phase. Application of α-linolenic acid and the extracts on chromatographic plates (band wise) was carried out by an automatic TLC sampler-4 (ATS-4) while the development of the plate took place in ADC-2 (Automatic Development Chamber-2). Post development, the plate was derivatized with vanillin sulfuric acid reagent and heated to give compact bands of the chosen marker compound. It was scanned and quantified densitometrically at λmax = 540 nm. The developed method was validated for precision, recovery, robustness, limits of detection (LOD), and limits of quantification (LOQ) in accordance with ICH guidelines.

5. Conclusions

Chromatographic investigation of the aerial parts of the edible plant S. irio resulted in the isolation of eight compounds, of which four (14) are unsaturated fatty acids and the other four (58) are identified as indole alkaloids. The structure of compound 4 was established as the fatty acid 8,11,12-trihydroxy-9Z,15Z-octadecadienoic acid, which is reported here for the first time from a natural source. Different spectroscopic techniques such as 1D, 2D NMR, and MS were employed to confirm the identity of the isolated compounds. Further, in silico molecular docking studies of compounds 1–4 were performed against PPAR-γ, which confirmed the agonist activity of compound 3 with a binding energy of −7.4 kcal mol−1 compared to the antidiabetic drug rivoglitazone. Similarly, molecular docking studies of compounds 58 were performed against serotonin receptor subtypes, namely 5-HT1A and 5-HT2A. Compound 8 exhibited notable docking scores, suggesting the strongest affinity among the tested indoles, with binding energies of −6.9 kcal/mol to 5HT1A and −8.1 kcal/mol to 5HT2A, respectively, against serotonin and risperidone as positive controls. The stability of target protein and compound complexes was tested by performing molecular dynamics simulations and analyzing parameters such as RMSD, RMSF, Rg, and SASA, which confirmed the formation of stable protein complexes. Further, principal component analysis (PCA) was used to collectively monitor the motion of amino acid residues of target proteins (PPAR-γ, 5-HT1A, and 5-HT2A) in the presence of their respective compounds. In addition, an HPTLC method was developed for the quantification of the biomarker compound 2, which guarantees its application in quality control of commercialized herbal drugs and formulations containing α-linolenic acid. This study’s outcome may serve as a scaffold to construct novel derivatives with higher potency and desirable drug-like properties. However, further validations through in vitro and in vivo studies are required.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph16040498/s1, Figure S1: Chemical structures of the isolated compounds (18), Figures S2–S8: 1D, 2D NMR, and HRESIMS spectra of compound 4, Figure S9: Bioavailability radar representations of the isolated compounds (18), Figure S10: Boiled-egg graph of blood–brain barrier (BBB) permeability and human gastrointestinal absorption (HIA), glycoprotein substrate (PGP+), and non-substrate (PGP), Figure S11: Chromatogram of HPTLC analysis of linolenic acid in hexane extract of S. irio (aerial parts); Table S1: 1H (500 MHz) and 13C (125 MHz) NMR data of compounds 1, 2, and 3, Table S2: 1H (500 MHz) and 13C (125 MHz) NMR data of compounds 58, Table S3: Binding parameters for the interaction of S. irio compounds 14 with PPAR-γ, Table S4: Binding parameters for the interaction of S. irio compounds 58 with the 5-HT1A serotonin receptor, Table S5: Binding parameters for the interaction of S. irio compounds 58 with the 5-HT2A serotonin receptor.

Author Contributions

Conceptualization, S.M.A.-M., M.F.A. and A.A.E.G.; methodology, S.M.A.-M., L.S.A., I.A.A., M.W.M.A., O.A.B., M.S.A.-K., M.F.A. and A.A.E.G.; software, F.M.A.B., M.W.M.A. and M.T.R.; validation, M.M.A.T., L.S.A., I.A.A., O.A.B. and M.S.A.-K.; formal analysis, L.S.A., P.A., M.W.M.A. and M.T.R.; investigation, M.M.A.T., S.M.A.-M., M.S.A.-K., M.F.A. and A.A.E.G.; resources, L.S.A., P.A., I.A.A., M.W.M.A. and M.T.R.; data curation, F.M.A.B., M.W.M.A., M.T.R. and M.F.A.; writing—original draft preparation, F.M.A.B., P.A., S.M.A.-M., L.S.A., I.A.A., M.T.R., O.A.B. and M.F.A.; writing—review and editing, all authors; supervision, M.S.A.-K., M.F.A. and A.A.E.G.; project administration, S.M.A.-M. and A.A.E.G.; funding acquisition, A.A.E.G. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia through project no. (IFKSURG-2-725).

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through project no. (IFKSURG-2-725).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rahman, M.; Khatun, A.; Liu, L.; Barkla, B.J. Brassicaceae Mustards: Traditional and Agronomic Uses in Australia and New Zealand. Molecules 2018, 23, 231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Zorzan, M.; Zucca, P.; Collazuol, D.; Peddio, S.; Rescigno, A.; Pezzani, R. Sisymbrium officinale, the Plant of Singers: A Review of Its Properties and Uses. Planta Med. 2020, 86, 1088–9928. [Google Scholar] [CrossRef] [PubMed]
  3. Tiwari, M.; Bhargava, P. Current updates on Sisymbrium irio linn: A traditional medicinal plant. Plant Arch. 2021, 21, 411–419. [Google Scholar] [CrossRef]
  4. Borgonovo, G.; Zimbaldi, N.; Guarise, M.; Bedussi, F.; Winnig, M.; Vennegeerts, T.; Bassoli, A. Glucosinolates in Sisymbrium officinale (L.) Scop.: Comparative analysis in cultivated and wild plants and In Vitro assays with T2Rs bitter taste receptors. Molecules 2019, 24, 4572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Al-Jaber, N.A. Phytochemical and biological studies of Sisymbrium irio L. Growing in Saudi Arabia. J. Saudi Chem. Soc. 2011, 15, 345–350. [Google Scholar] [CrossRef] [Green Version]
  6. Guil-Guerrero, J.; Giménez-Martínez, J.; Torija-Isasa, M. Nutritional composition of wild edible Crucifer species. J. Food Biochem. 2007, 23, 283–294. [Google Scholar] [CrossRef]
  7. Shah, S.; Rehmanullah, S.; Muhammad, Z. Pharmacognostic standardization and pharmacological study of Sisymbrium irio L. Am. J. Res. Commun. 2013, 1, 241–253. [Google Scholar]
  8. Khalil, H.E.; Aljeshi, Y.M.; Saleh, F.A. Phytochemical Analysis and In Vitro Antioxidant Properties of Sisymbrium irio L. Growing in Saudi Arabia: A Comparative Study. Res. J. Pharm. Biol. Chem. Sci. 2017, 8, 2533–2540. [Google Scholar]
  9. Hailu, B.T.; Gupta, R.K.; Rani, A. Sisymbrium irio L: An Herb used in the Unani system of medicine for broad spectrum therapeutical applications. Indian. J. Tradit. Knowl. 2019, 18, 140–143. [Google Scholar]
  10. Rajapaksha, H.; Bhatia, H.; Wegener, K.; Petrovsky, N.; Bruning, J.B. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs. Biochim. Biophys. Acta Gen. Subj. 2017, 1861, 1981–1991. [Google Scholar] [CrossRef]
  11. Bockaert, J.; Claeysen, S.; Bécamel, C.; Dumuis, A.; Marin, P. Neuronal 5-HT metabotropic receptors: Fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006, 326, 553–572. [Google Scholar] [CrossRef]
  12. Kemp, D.E.; Canan, F.; Goldstein, B.I.; McIntyre, R.S. Long-acting risperidone: A review of its role in the treatment of bipolar disorder. Adv. Ther. 2009, 26, 588–599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Al-Wahaibi, L.H.; Rehman, M.T.; Al-Saleem, M.S.M.; Basudan, O.A.; El-Gamal, A.A.; AlAjmi, M.F.; Backheet, E.Y.; Khalifa, A.A.; Abdel-Mageed, W.M. Phenolics from the heartwood of Tecoma mollis as potential inhibitors of COVID-19 virus main protease and spike proteins: An In silico study. Pharmacogn. Mag. 2021, 17, 278–286. [Google Scholar]
  14. Saikia, S.; Bordoloi, M. Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective. Curr. Drug Targets 2019, 20, 501–521. [Google Scholar] [CrossRef]
  15. Asilbekova, D.T.; Ozek, G.; Ozek, T.; Bobakulov, K.M.; Baser, K.H.C.; Sagdullaev, S.S. Essential oil and lipids from leaves of Ferula kuhistanica. Chem. Nat. Compd. 2019, 55, 993–998. [Google Scholar] [CrossRef]
  16. Kazemeini, S.; Tarzi, B.; Bakhoda, H.; Larijani, K.; Damanafshan, P. Evaluation of the minerals content and fatty acids profiles in Descurainia Sophia and Sisymbrium irio. Bulg. Chem. Commun. 2015, 47, 112–118. [Google Scholar]
  17. Alexandri, E.; Ahmed, R.; Siddiqui, H.; Choudhary, M.I.; Tsiafoulis, C.G.; Gerothanassis, I.P. High Resolution NMR Spectroscopy as a Structural and Analytical Tool for Unsaturated Lipids in Solution. Molecules 2017, 22, 1663. [Google Scholar] [CrossRef] [Green Version]
  18. Al-Qudah, M.A.; Abu Zarga, M.H. Chemical constituents of Sisymbrium irio L. from Jordan. Nat. Prod. Res. 2010, 24, 448–456. [Google Scholar] [CrossRef]
  19. Prajapati, R.; Seong, S.H.; Kim, H.R.; Jung, H.A.; Choi, J.S. Isolation and identification of bioactive compounds from the tuber of Brassica oleracea var. gongylodes. Nat. Prod. Sci. 2010, 26, 214–220. [Google Scholar]
  20. Monde, K.; Sasaki, K.; Shirata, A.; Takasugi, M. Studies on stress metabolites. Part 15. Metboxybrassenins A and B, sulfur-containing stress metabolites from Brassica oleracea var. capitata. Phytochemistry 1991, 30, 3921–3922. [Google Scholar] [CrossRef]
  21. Alhadrami, H.A.; Thissera, B.; Hassan, M.H.A.; Behery, F.A.; Ngwa, C.J.; Hassan, H.M.; Pradel, G.; Abdelmohsen, U.R.; Rateb, M.E. Bio-Guided isolation of antimalarial metabolites from the coculture of two red sea sponge-derived Actinokineospora and Rhodococcus spp. Mar. Drugs 2021, 19, 109. [Google Scholar] [CrossRef] [PubMed]
  22. Yang, X.; Wong, M.; Wang, N.; Chan, A.S.; Yao, X. A new eudesmane derivative and a new fatty acid ester from Sambucus williamsii. Chem. Pharm. Bull. 2006, 54, 676–678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Ben Nejma, A.; Znati, M.; Nguir, A.; Daich, A.; Othman, M.; Lawson, A.M.; Ben Jannet, H. Phytochemical and biological studies of Atriplex inflata f. Muell.: Isolation of secondary bioactive metabolites. J. Pharm. Pharmacol. 2017, 69, 1064–1074. [Google Scholar] [CrossRef]
  24. Brown, T.J.; Brainard, J.; Song, F.; Wang, X.; Abdelhamid, A.; Hooper, L. PUFAH Group. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: Systematic review and meta-analysis of randomised controlled trials. BMJ 2019, 366, l4697. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Wang, J.; Han, L.; Wang, D.; Li, P.; Shahidi, F. Conjugated Fatty Acids in Muscle Food Products and Their Potential Health Benefits: A Review. J. Agric. Food Chem. 2020, 68, 13530–13540. [Google Scholar] [CrossRef]
  26. Popp-Snijders, C.; Schouten, J.A.; Heine, R.J.; van der Meer, J.; van der Veen, E.A. Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes. Diabetes Res. 1987, 4, 141–147. [Google Scholar]
  27. Hawash, M.; Jaradat, N.; Elaraj, J.; Hamdan, A.; Lebdeh, S.A.; Halawa, T. Evaluation of the hypoglycemic effect of seven wild folkloric edible plants from Palestine. J. Complement. Integr. Med. 2019, 17, 20190032. [Google Scholar] [CrossRef]
  28. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef] [Green Version]
  29. Rochat, B.; Baumann, P.; Audus, K.L. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res. 1999, 831, 229–236. [Google Scholar] [CrossRef]
  30. Jabir, N.R.; Rehman, M.T.; Tabrez, S.; Alserihi, R.F.; AlAjmi, M.F.; Khan, M.S.; Husain, F.M.; Ahmed, B.A. Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer’s Treatment: A Computational Strategy. Curr. Pharm. Des. 2021, 27, 2425–2434. [Google Scholar] [CrossRef]
  31. Jolliffe, I.T. Principal Component Analysis; Springer Series in Statistics; Springer: New York, NY, USA, 2002. [Google Scholar]
  32. Harper, C.R.; Edwards, M.J.; DeFilipis, A.P.; Jacobson, T.A. Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. J. Nutr. 2006, 136, 83–87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Gomes, P.M.; Hollanda-Miranda, W.R.; Beraldo, R.A.; Castro, A.V.; Geloneze, B.; Foss, M.C.; Foss-Freitas, M.C. Supplementation of α-linolenic acid improves serum adiponectin levels and insulin sensitivity in patients with type 2 diabetes. Nutrition 2015, 31, 853–857. [Google Scholar] [CrossRef] [PubMed]
  34. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O’Rahilly, S.; et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58, 726–741. [Google Scholar] [CrossRef] [PubMed]
  35. Holliday, N.D.; Watson, S.J.; Brown, A.G. Drug discovery opportunities and challenges at G protein coupled receptors for long chain free fatty acids. Front. Endocrinol. 2011, 2, 112. [Google Scholar] [CrossRef] [Green Version]
  36. Grygiel-Górniak, B. Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications—A review. Nutr. J. 2014, 13, 17. [Google Scholar] [CrossRef] [Green Version]
  37. Hamid, H.A.; Ramli, A.N.; Yusoff, M.M. Indole alkaloids from plants as potential leads for antidepressant drugs: A Mini Review. Front. Pharmacol. 2017, 8, 96. [Google Scholar] [CrossRef] [Green Version]
  38. Ndombera, F.T.; Maiyoh, G.K.; Tuei, V.C. Pharmacokinetic, Physicochemical and Medicinal Properties of N-glycoside Anti-cancer Agent More Potent than 2-Deoxy-D-Glucose in Lung Cancer Cells. J. Pharm. Pharmacol. 2019, 7, 165–176. [Google Scholar]
  39. Hoosain, F.G.; Choonara, Y.E.; Tomar, L.K.; Kumar, P.; Tyagi, C.; du Toit, L.C.; Pillay, V. Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. Biomed. Res. Int. 2015, 2015, 484963. [Google Scholar] [CrossRef] [Green Version]
  40. Chen, C.; Lee, M.-H.; Weng, C.-F.; Leong, M.K. Theoretical Prediction of the Complex P-Glycoprotein Substrate Efflux Based on the Novel Hierarchical Support Vector Regression Scheme. Molecules 2018, 23, 1820. [Google Scholar] [CrossRef] [Green Version]
  41. Kumarnsit, E.; Vongvatcharanon, U.; Keawpradub, N.; Intasaro, P. Fos-like immunoreactivity in rat dorsal raphe nuclei induced by alkaloid extract of Mitragyna speciosa. Neurosci. Lett. 2007, 416, 128–132. [Google Scholar] [CrossRef]
  42. Jawna-Zboińska, K.; Blecharz-Klin, K.; Joniec-Maciejak, I.; Wawer, A.; Pyrzanowska, J.; Piechal, A.; Mirowska-Guzel, D.; Widy-Tyszkiewicz, E. Passiflora incarnata L. Improves Spatial Memory, Reduces Stress, and Affects Neurotransmission in Rats. Phytother. Res. 2016, 30, 781–789. [Google Scholar] [CrossRef] [PubMed]
  43. Al-Shabib, N.A.; Khan, J.M.; Malik, A.; Alsenaidy, M.A.; Rehman, M.T.; AlAjmi, M.F.; Alsenaidy, A.M.; Husain, F.M.; Khan, R.H. Molecular insight into binding behavior of polyphenol (rutin) with beta lactoglobulin: Spectroscopic, molecular docking and MD simulation studies. J. Mol. Liq. 2018, 269, 511–520. [Google Scholar] [CrossRef]
  44. Al-Saleem, M.S.M.; Al-Wahaibi, L.H.; Rehman, M.T.; AlAjmi, M.F.; Alkahtani, R.A.; Abdel-Mageed, W.M. Phenolic compounds of Heliotropium europaeum and their biological activities. Pharmacogn. Mag. 2020, 16, 108–116. [Google Scholar]
  45. Tan, Y.; Xu, P.; Huang, S.; Yang, G.; Zhou, F.; He, X.; Ma, H.; Xu, H.E.; Jiang, Y. Structural insights into the ligand binding and Gi coupling of serotonin receptor 5-HT5A. Cell Discov. 2022, 8, 50–58. [Google Scholar] [CrossRef]
  46. Kimura, K.T.; Asada, H.; Inoue, A.; Kadji, F.; Im, D.; Mori, C.; Arakawa, T.; Hirata, K.; Nomura, Y.; Nomura, N.; et al. Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine. Nat. Struct. Mol. Biol. 2019, 26, 121–128. [Google Scholar] [CrossRef] [PubMed]
  47. Rehman, M.T.; AlAjmi, M.F.; Hussain, A. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19. Curr. Pharm. Des. 2021, 27, 3577–3589. [Google Scholar] [CrossRef] [PubMed]
  48. AlAjmi, M.F.; Azhar, A.; Owais, M.; Rashid, S.; Hasan, S.; Hussain, A.; Rehman, M.T. Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19. J. Biomol. Struct. Dyn. 2021, 39, 6676–6688. [Google Scholar] [CrossRef]
  49. Branka, A.C. Nose-Hoover chain method for nonequilibrium molecular dynamics simulation. Phys. Rev. E Stat. Phys. Plasmas Fluids Relat. Interdiscip. Topics 2000, 61, 4769–4773. [Google Scholar]
  50. Martyna, G.J.; Tobias, D.J.; Klein, M.L. Constant pressure molecular dynamics algorithms. J. Chem. Phys. 1994, 101, 4177–4189. [Google Scholar] [CrossRef]
  51. Iqbal, D.; Rehman, M.T.; Bin Dukhyil, A.; Rizvi, S.; Al Ajmi, M.F.; Alshehri, B.M.; Banawas, S.; Khan, M.S.; Alturaiki, W.; Alsaweed, M. High-Throughput Screening and Molecular Dynamics Simulation of Natural Product-like Compounds against Alzheimer’s Disease through Multitarget Approach. Pharmaceuticals 2021, 14, 937. [Google Scholar] [CrossRef]
  52. Ichiye, T.; Karplus, M. Collective motions in proteins: A covariance analysis of atomic fluctuations in molecular dynamics and normal mode simulations. Proteins 1991, 11, 205–217. [Google Scholar] [CrossRef] [PubMed]
  53. Grant, B.J.; Skjaerven, L.; Yao, X.Q. The Bio3D packages for structural bioinformatics. Protein Sci. 2021, 30, 20–30. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Chemical structures of the isolated compounds (18) from Sisymbrium irio L.
Figure 1. Chemical structures of the isolated compounds (18) from Sisymbrium irio L.
Pharmaceuticals 16 00498 g001
Figure 2. 1H-1H COSY (―) and key 1H-13C HMBC (HC) correlations of compound 4.
Figure 2. 1H-1H COSY (―) and key 1H-13C HMBC (HC) correlations of compound 4.
Pharmaceuticals 16 00498 g002
Figure 3. Molecular docking of isolated SI fatty acids and rivoglitazone (control) with PPAR-γ. (A) Two-dimensional representation of ligands binding to the protein; (B) three-dimensional representation of ligands binding at the cavity of the protein; and (C) molecular interaction and the amino acid residues involved in stabilizing rivoglitazone (control) and PPAR-γ complex formation.
Figure 3. Molecular docking of isolated SI fatty acids and rivoglitazone (control) with PPAR-γ. (A) Two-dimensional representation of ligands binding to the protein; (B) three-dimensional representation of ligands binding at the cavity of the protein; and (C) molecular interaction and the amino acid residues involved in stabilizing rivoglitazone (control) and PPAR-γ complex formation.
Pharmaceuticals 16 00498 g003
Figure 4. Molecular interaction between isolated SI fatty acids and PPAR-γ. (A) Compound 1, (B) compound 2, (C) compound 3, and (D) compound 4.
Figure 4. Molecular interaction between isolated SI fatty acids and PPAR-γ. (A) Compound 1, (B) compound 2, (C) compound 3, and (D) compound 4.
Pharmaceuticals 16 00498 g004
Figure 5. Molecular docking of isolated SI indole compounds and serotonin with 5-HT1A. (A) Two-dimensional representation of ligands binding to the protein; (B) three-dimensional representation of ligands binding at the cavity of the protein; and (C) molecular interaction and the amino acid residues involved in stabilizing serotonin (control) and 5-HT1A complex formation.
Figure 5. Molecular docking of isolated SI indole compounds and serotonin with 5-HT1A. (A) Two-dimensional representation of ligands binding to the protein; (B) three-dimensional representation of ligands binding at the cavity of the protein; and (C) molecular interaction and the amino acid residues involved in stabilizing serotonin (control) and 5-HT1A complex formation.
Pharmaceuticals 16 00498 g005
Figure 6. Molecular interaction between SI indole compounds and 5-HT1A. (A) Compound 5, (B) compound 6, (C) compound 7, and (D) compound 8.
Figure 6. Molecular interaction between SI indole compounds and 5-HT1A. (A) Compound 5, (B) compound 6, (C) compound 7, and (D) compound 8.
Pharmaceuticals 16 00498 g006
Figure 7. Molecular docking of isolated SI indole compounds and resperidone with 5-HT2A. (A) Two-dimensional representation of ligands binding to the protein; (B) three-dimensional representation of ligands binding at the cavity of the protein; and (C) molecular interaction and the amino acid residues involved in stabilizing resperidone (control) and 5-HT2A complex formation.
Figure 7. Molecular docking of isolated SI indole compounds and resperidone with 5-HT2A. (A) Two-dimensional representation of ligands binding to the protein; (B) three-dimensional representation of ligands binding at the cavity of the protein; and (C) molecular interaction and the amino acid residues involved in stabilizing resperidone (control) and 5-HT2A complex formation.
Pharmaceuticals 16 00498 g007
Figure 8. Molecular interaction between S. irio compounds and 5-HT2A. (A) Compound 5, (B) compound 6, (C) compound 7, and (D) compound 8.
Figure 8. Molecular interaction between S. irio compounds and 5-HT2A. (A) Compound 5, (B) compound 6, (C) compound 7, and (D) compound 8.
Pharmaceuticals 16 00498 g008
Figure 9. Root mean square deviation (RMSD) in the Cα-atoms of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3; (B) 5-HT1A alone and in the presence of compound 8; (C) 5-HT1A alone and in the presence of compound 8.
Figure 9. Root mean square deviation (RMSD) in the Cα-atoms of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3; (B) 5-HT1A alone and in the presence of compound 8; (C) 5-HT1A alone and in the presence of compound 8.
Pharmaceuticals 16 00498 g009
Figure 10. Root mean square fluctuation (RMSF) in the Cα-atoms of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3; (B) 5-HT1A alone and in the presence of compound 8; (C) 5-HT1A alone and in the presence of compound 8.
Figure 10. Root mean square fluctuation (RMSF) in the Cα-atoms of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3; (B) 5-HT1A alone and in the presence of compound 8; (C) 5-HT1A alone and in the presence of compound 8.
Pharmaceuticals 16 00498 g010
Figure 11. Variation in radius of gyration (Rg) of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3; (B) 5-HT1A alone and in the presence of compound 8; (C) 5-HT2A alone and in the presence of compound 8.
Figure 11. Variation in radius of gyration (Rg) of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3; (B) 5-HT1A alone and in the presence of compound 8; (C) 5-HT2A alone and in the presence of compound 8.
Pharmaceuticals 16 00498 g011
Figure 12. Variation in solvent-accessible surface area (SASA) of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3, (B) 5-HT1A alone and in the presence of compound 8, (C) 5-HT2A alone and in the presence of compound 8.
Figure 12. Variation in solvent-accessible surface area (SASA) of PPAR-γ, 5-HT1A, and 5-HT2A with their respective compounds. (A) PPAR-γ alone and in the presence of compounds 1 and 3, (B) 5-HT1A alone and in the presence of compound 8, (C) 5-HT2A alone and in the presence of compound 8.
Pharmaceuticals 16 00498 g012
Figure 13. Principal component analysis (PCA) of PPAR-γ, 5-HT1A, and 5-HT2A in the absence and presence of their respective ligands. (A) PPAR-γ alone; (B) PPAR-γ in the presence of compound 1; (C) PPAR-γ in the presence of compound 3; (D) 5-HT1A alone; (E) 5-HT1A in the presence of compound 8; (F) 5-HT2A alone; and (G) 5-HT2A in the presence of compound 8.
Figure 13. Principal component analysis (PCA) of PPAR-γ, 5-HT1A, and 5-HT2A in the absence and presence of their respective ligands. (A) PPAR-γ alone; (B) PPAR-γ in the presence of compound 1; (C) PPAR-γ in the presence of compound 3; (D) 5-HT1A alone; (E) 5-HT1A in the presence of compound 8; (F) 5-HT2A alone; and (G) 5-HT2A in the presence of compound 8.
Pharmaceuticals 16 00498 g013
Table 1. 1H (500 MHz) and 13C NMR (125 MHz) data (in CD3OD) for compound 4.
Table 1. 1H (500 MHz) and 13C NMR (125 MHz) data (in CD3OD) for compound 4.
No.4
δC, Mult.δH, Mult (J in Hz)
1177.9, C  -
2 35.0, CH2  2.16, t (7.3)
3 26.0, CH2  1.48, br t (7.2)
4 30.1, CH2  1.22, m
5 30.3, CH2  1.22, m
6 26.4, CH2  1.22, m
7 38.2, CH2  1.41, m
8 73.0, CH  3.98, m
9136.5, CH  5.60, m
10131.0, CH  5.60, m
11 75.8, CH  3.85, t (6.0)
12 75.7, CH  3.38, m
13 31.5, CH2a. 2.24, m
b. 2.02, m
14 30.5, CH2  1.22, m
15126.3, CH  5.34, m
16134.4, CH  5.34, m
17 21.6, CH2  1.95 br. t (6.5)
18 14.6, CH3  0.85, t (7.4)
Table 2. Molecular docking parameters for the interaction of isolated SI fatty acids (14) with PPAR-γ.
Table 2. Molecular docking parameters for the interaction of isolated SI fatty acids (14) with PPAR-γ.
CompoundΔG kcal mol−1Receptor Amino Acids
Rivoglitazone−8.2ARG280, ILE281, PHE282, GLY284, CYS285, GLN286, ARG288, SER289, HIS323, ILE326, TYR327, LEU330, VAL339, ILE341, MET348, LEU353, MET364, HIS449, LEU453, LEU469, TYR473
1−6.7PHE226, CYS285, GLN286, ARG288, SER289, ALA292, GLU295, ILE296, HIS323, ILE325, ILE326, TYR327, MET329, LEU330, LEU333, LYS367, HIS449, LEU453, LEU465, LEU469, TYR473
2−6.0LEU228, PHE282, CYS285, GLN286, ARG288, SER289, ALA292, HIS323, ILE326, TYR327, MET329, LEU330, SER332, LEU333, PHE363, MET364, HIS449, LEU453, LEU465, LEU469, TYR473
3−7.4LEU228, ILE281, PHE282, CYS285, GLN286, ARG288, SER289, ALA292, ILE326, TYR327, MET329, LEU330, SER332, LEU333, LEU356, PHE360, PHE363, MET364, LYS367, HIS449
4−6.1PHE282, CYS285, GLN286, ARG288, SER289, ALA292, HIS323, ILE326, TYR327, MET329, LEU330, LEU333, PHE363, MET364, LYS367, HIS449, LEU453, LEU465, LEU469, TYR473
Arg: Arginine; Ile: Isoleucine; Phe: Phenylalanine; Gly: Glycine; Cys: Cysteine; Gln: Glutamine; Ser: Serine; His: Histidine; Tyr: Tyrosine; Leu: Leucine; Val: Valine; Met: Methionine; Glu: Glutamic acid; Ala: Alanine.
Table 3. Molecular docking parameters for the interaction of isolated indole compounds (58) with 5-HT1A serotonin receptor.
Table 3. Molecular docking parameters for the interaction of isolated indole compounds (58) with 5-HT1A serotonin receptor.
CompoundΔG kcal mol−1Receptor Amino Acids
Serotonin−6.1ASP116, VAL117, CYS120, THR121, ILE124, ILE167, ILE189, SER199, ALA203, PHE361, PHE362, ALA365, ASN386, TYR390
5−6.4ASP116, VAL117, CYS120, THR121, ILE124, ALA203, TRP358, PHE361, PHE362, ASN386, GLY389, TYR390
6−6.4ASP116, VAL117, CYS120, THR121, ILE124, ILE189, THR196, SER199, THR200, ALA203, PHE361, PHE362, ALA365
7−6.5ASP116, VAL117, CYS120, THR121, ILE124, ILE189, TRY195, SER199, ALA203, PHE362
8−6.9VAL117, ILE189, SER190, LYS191, TYR195, THR196, SER199, THR200, PHE361, PHE362, ALA365, PRO369
Ala: Alanine; Asn: Asparagine; Asp: Aspartic acid; Cys: Cysteine; Gly: Glycine; Ile: Isoleucine; Lys: Lysine; Phe: Phenylalanine; Pro: Proline; Ser: Serine; Thr: Threonine; Tyr: Tyrosine; Val: Valine.
Table 4. Molecular docking parameters for the interaction of isolated SI indole compounds (58) with 5-HT2A serotonin receptor.
Table 4. Molecular docking parameters for the interaction of isolated SI indole compounds (58) with 5-HT2A serotonin receptor.
CompoundΔG kcal mol−1Receptor Amino Acids
Risperidone−11.8SER131, TYR139, TRP151, ASP155, VAL156, SER159, THR160, ILE163, LEU228, GLY238, SER242, PHE243, PHE332, TRP336, PHE339, PHE340, ASN363, VAL366, TYR370
5−7.3ASP155, VAL156, SER159, THR160, ILE163, TRP336, SER242, PHE243, PHE332, TRP336, PHE339, PHE340, TYR370
6−7.5ASP155, VAL156, SER159, THR160, ILE163, GLY238, SER242, PHE243, PHE332, TRP336, PHE339, PHE340
7−7.4LEU123, ASP155, VAL156, SER159, THR160, ILE163, GLY238, SER242, PHE243, PHE332, TRP336, PHE339, PHE340, TYR370
8−8.1LEU123, ASP155, VAL156, SER159, THR160, ILE163, SER242, PHE243, PHE332, TRP336, PHE339, PHE340, VAL366, TYR370
Table 5. The predictive physicochemical, pharmacokinetic, drug-likeness, and toxicity properties of isolated SI compounds (18).
Table 5. The predictive physicochemical, pharmacokinetic, drug-likeness, and toxicity properties of isolated SI compounds (18).
PropertyCompound ID
12345678
Molecular weight250.38278.43330.46328.44186.2140156.18190.2020203.2450
Molecular formulaC16H26O2C18H30O2C18H34O5C18H32O5C11H10N2OC11H10N2OC10H10N2O2C11H13N3O
Lipophilicity (Log Po/w)4.885.663.022.802.231.770.800.52
Water solubility (ESOL)InsolubleInsolubleSoluble
(−2.88)
Soluble
(−2.88)
Soluble
(−2.64)
Soluble
(−2.31)
Soluble
(−2.47)
Very soluble
(−1.71)
TPSA37.337.397.9997.9937.9539.5857.2584.9
LipinskiYesYesYesYesYesYesYesYes
GIT absorption------HighHighHighHighHighHigh
BBB permeability------NoNoYesYesYesNo
P-gp substrate------YesYesNoNoNoNo
Bioavailability score------0.560.560.550.550.550.55
H-bond (donors/acceptors)1/21/24/54/50/21/11/23/2
CYP450-1A2------NoNoYesYesYesNo
CYP2D6------YesYesNoNoNoNo
CYP2C19/2C9/3A4------NoNoNoNoNoNo
PAINSNoNoNoNoNoNoNoNo
Table 6. Calculation of free energy (MM-GBSA) for the interactions between PPAR-γ and 5-HT1A with the SI compounds (18).
Table 6. Calculation of free energy (MM-GBSA) for the interactions between PPAR-γ and 5-HT1A with the SI compounds (18).
Target ProteinCompoundsΔG
or
ΔGBind
ΔGCoulombΔGCovalentΔGH-bondΔGSA
or
ΔGSol_Lipo
ΔGPackingΔGSolv
or
ΔGSolGB
ΔGvdW
PPAR-γCompound 1−54.55−46.2010.06−2.74−8.54−5.2051.15−53.08
Compound 2−45.58−18.226.91−2.11−15.70−0.4919.58−35.55
Compound 3−57.23−52.929.92−3.90−11.13−4.3055.84−50.74
Compound 4−49.86−31.732.89−3.04−8.09−1.7130.21−38.39
5-HT1ACompound 5−52.79−11.855.18−2.37−17.41−5.5418.30−39.10
Compound 6−44.922.00−0.49−1.54−10.24−4.991.81−31.47
Compound 7−55.02−18.202.84−1.68−17.12−7.5621.31−34.61
Compound 8−57.98−9.784.95−1.19−19.13−4.5612.31−40.58
5-HT2ACompound 5−28.18−23.5817.14−2.13−13.08−1.5825.34−30.29
Compound 6−45.58−18.226.91−2.11−15.70−0.4919.58−35.55
Compound 7−36.15−17.540.83−1.16−8.45−7.3613.55−16.02
Compound 8−57.90−9.784.95−1.19−19.13−4.5612.31−40.5
All energies are in kcal mol−1. ΔGCoulomb, ΔGvdW, ΔGCovalent, ΔGSolv or ΔGSolGB, ΔGH-bond, ΔGSA or ΔGSol-Lipo, ΔGPacking, and ΔG or ΔGBind stand for minimized molecular mechanics energy, Coulomb energy, van der Waals energy, covalent binding energy, solvation energy, energy due to self-contact, energy due to H-bonds, lipophilic energy, packing energy, and binding energy, respectively.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Al-Massarani, S.M.; Aldurayhim, L.S.; Alotaibi, I.A.; Abdelmageed, M.W.M.; Rehman, M.T.; Basudan, O.A.; Abdel-Kader, M.S.; Alajmi, M.F.; Abdel Bar, F.M.; Alam, P.; et al. Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L. Pharmaceuticals 2023, 16, 498. https://doi.org/10.3390/ph16040498

AMA Style

Al-Massarani SM, Aldurayhim LS, Alotaibi IA, Abdelmageed MWM, Rehman MT, Basudan OA, Abdel-Kader MS, Alajmi MF, Abdel Bar FM, Alam P, et al. Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L. Pharmaceuticals. 2023; 16(4):498. https://doi.org/10.3390/ph16040498

Chicago/Turabian Style

Al-Massarani, Shaza M., Latifah S. Aldurayhim, Ibtisam A. Alotaibi, Mostafa W. M. Abdelmageed, Md Tabish Rehman, Omer A. Basudan, Maged S. Abdel-Kader, Mohamed F. Alajmi, Fatma M. Abdel Bar, Perwez Alam, and et al. 2023. "Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L." Pharmaceuticals 16, no. 4: 498. https://doi.org/10.3390/ph16040498

APA Style

Al-Massarani, S. M., Aldurayhim, L. S., Alotaibi, I. A., Abdelmageed, M. W. M., Rehman, M. T., Basudan, O. A., Abdel-Kader, M. S., Alajmi, M. F., Abdel Bar, F. M., Alam, P., Al Tamimi, M. M., & El Gamal, A. A. (2023). Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L. Pharmaceuticals, 16(4), 498. https://doi.org/10.3390/ph16040498

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop